Zealand reports positive results on type 2 diabetes drug
Lixisenatide QD had a greater post-prandial glucose lowering (PPG) effect than liraglutide QD in patients with Type 2 diabetes (-129% versus -41%, respectively). It is accompanied by significant
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.